ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1308

Answering Reproductive Health Questions That Your Patients Want to Know: Impediments to Family Building and Risks of Contraception

Malithi Jayasundara1, Amanda M. Eudy2, Tayseer Haroun3, W. Benjamin Nowell4, Jeffrey R. Curtis5, Rachelle Crow-Hercher6, Charlotte Whitney White6, Seth D. Ginsberg7 and Megan E. B. Clowse8, 1Rheumatology, Duke University, Durham, NC, 2Duke University, Durham, NC, 3Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, 4Global Healthy Living Foundation, Upper Nyack, NY, 5University of Alabama at Birmingham, Birmingham, AL, 6Arthritis Power, Upper Nyack, NY, 7Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, 8Duke University Medical Center, Durham, NC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Arthritis, family studies, hormones, patient outcomes and women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Women with arthritis wonder whether they will be able to have the children they desire. They also worry that oral contraceptives may worsen their arthritis. Working with the Patient Governors of an inflammatory arthritis network, we developed a reproductive survey to answer these questions.

Methods:

The survey was developed in a collaboration between the research and patient teams. The survey was distributed via email to the network’s participant list and consent was implied the women clicked on the link to join the anonymous survey. This study is limited by selection and recall bias.

Results:

From March to June 2017 14,711 invitations were sent with 250 female responses. Self-reported diagnoses of RA (80%) and SpA (24%) were hampered by many women reporting multiple diagnoses. The majority of respondents were white (83%), non-Hispanic (82%), with a college degree (69%).

Of all women, 59% had fewer children than they desired due to arthritis and 36% had the full number they wanted. Women who had fewer children had an earlier age of diagnosis compared to those did not (24.5yrs vs 31.6yrs, p<0.0001). The most common fears limiting family size were 1.) being unable to care for a child (85%), 2.) arthritis medications would harm child (61%), and 3.) the child would get arthritis (52%).

Of the women who tried to conceive after their arthritis diagnosis, 44% reported infertility (23% with physician-diagnosed infertility and 42% taking >1yr to conceive). Unexplained infertility (39%) was the most common cause, followed by ovulation dysfunction (37%), endometriosis (26%), and uterine/tubal issues (26%). Women with physician-diagnosed infertility were younger at arthritis diagnosis than fertile women (24.6yrs vs 31.4yrs, p=0.007). Half of the women with infertility used multiple forms of assisted reproductive technology, including oral (27) and injectable (16) medications and IVF (7).

Of the women not pregnant, trying to become pregnant, or in a same-sex relationship, 35% reported currently using highly effective, 32% effective, and 33% ineffective contraception; 28% of women taking methotrexate were using ineffective contraception.

Of the 135 of women who report ever using OCP, 70% report no impact of the pills on their arthritis; 9% had improved arthritis and 10% had worsened arthritis. At the time of the survey, 20% of women were currently taking OCPs: more prior OCP users noted worsening of arthritis with the drugs than current OCP users (16% prior vs 2% current users, p=0.02)

Half of women noticed an effect of their menstrual cycle on their arthritis disease activity with the vast majority reporting worsening just prior to (60%) or during menstruation (36%). Multiple women reported that taking OCPs continuously, and thus avoiding their monthly menses, seemed to decrease their pre-menstrual flares.

Conclusion:

More than half of the women report having fewer children than they had ideally wanted, largely due to infertility and concerns about their medications and difficulty mothering. The frequency of ineffective contraceptive use among women on methotrexate remains unacceptably high. Fear of OCPs appears to be unfounded and continuous OCP use may provide relief for women with menses-related arthritis flares.


Disclosure: M. Jayasundara, None; A. M. Eudy, None; T. Haroun, None; W. B. Nowell, Pfizer, BMS, Lilly, Merck, JandJ, GSK, Mallincrodt, 1; J. R. Curtis, Amgen, Pfizer, Crescendo Bio, Corrona, 2,AbbVie, Roche/Genentech, BMS, UCB, Myriad, Amgen, Janssen, Pfizer, Corrona, 5; R. Crow-Hercher, None; C. Whitney White, None; S. D. Ginsberg, None; M. E. B. Clowse, Pfizer, Janssen, 5,UCB Pharma, 5.

To cite this abstract in AMA style:

Jayasundara M, Eudy AM, Haroun T, Nowell WB, Curtis JR, Crow-Hercher R, Whitney White C, Ginsberg SD, Clowse MEB. Answering Reproductive Health Questions That Your Patients Want to Know: Impediments to Family Building and Risks of Contraception [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/answering-reproductive-health-questions-that-your-patients-want-to-know-impediments-to-family-building-and-risks-of-contraception/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/answering-reproductive-health-questions-that-your-patients-want-to-know-impediments-to-family-building-and-risks-of-contraception/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology